Most recently, Edward Mascioli, M.D. has been CEO of Karos Pharmaceuticals, leading its sale to Roivant; and of Affinium Pharmaceuticals, also leading its sale to Debiopharm International. Prior to these CEO roles, Dr. Mascioli was at Pfizer where he established and led a novel unit in rare diseases. Dr. Mascioli has over a decade of experience in healthcare venture capital, having been a venture partner at SV Life Sciences, and an executive partner at MPM Capital. Dr. Mascioli has served as a director on the boards of Arriva Pharmaceuticals, Elixir Pharmaceuticals, Mindset BioPharmaceuticals, Oxagen, Ltd., and NKT Therapeutics, and as an observer on the boards of CGI Pharmaceuticals, Radius Health, and Peptimmune. Dr. Mascioli started his career on the faculty of Harvard Medical School as an assistant professor of medicine and on the staff of the Beth Israel Deaconess Hospital in Boston. Dr. Mascioli holds an M.S. from MIT, an M.D. from the University of Massachusetts Medical School, and a B.A. from Brandeis University.